[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"active-systemic-lupus-erythematosus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:active-systemic-lupus-erythematosus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100616868","phase-2-a-study-of-d-2570-in-patients-with-active-systemic-lupus-erythematosus-sle-100616868",false,"NCT07311200","A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Patients With Active Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* The patient voluntarily participates in this study after full informed consent.\n* The age is 18 years ≤ age ≤ 70 years, regardless of gender.\n* Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.\n* SLEDAI-2K total score ≥ 8.\n* On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.\n\nExclusion Criteria:\n\n* History of infection as defined in the protocol.\n* Any of the medical diseases or disorders listed in the protocol.\n* Significant, uncontrolled or unstable disease in any organ.","ALL","18 Years","70 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.",[27],"Active Systemic Lupus Erythematosus",[27],"RECRUITING","2026-04-23",{"date":32,"type":33},"2026-04-24","ACTUAL",{"date":35,"type":33},"2026-02-12",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"InventisBio Co., Ltd","INDUSTRY"]